Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BI-765179 by Boehringer Ingelheim International for Ovarian Cancer: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Ovarian Cancer. According to GlobalData,...
BI-765179 by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Colorectal Cancer. According to GlobalData,...
BI-765179 by Boehringer Ingelheim International for Cervical Cancer: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Cervical Cancer. According to GlobalData,...
BI-765179 by Boehringer Ingelheim International for Melanoma: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Melanoma. According to GlobalData, Phase...
BI-765179 by Boehringer Ingelheim International for Pancreatic Cancer: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Pancreatic Cancer. According to GlobalData,...
BI-765179 by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...
BI-765179 by Boehringer Ingelheim International for Hepatocellular Carcinoma: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...
BI-765179 by Boehringer Ingelheim International for Solid Tumor: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Solid Tumor. According to GlobalData,...
BI-765179 by Boehringer Ingelheim International for Malignant Pleural Mesothelioma: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Malignant Pleural Mesothelioma. According to...
BI-765179 by Boehringer Ingelheim International for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell...
BI-765179 by Boehringer Ingelheim International for Non-Small Cell Lung Carcinoma: Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Carcinoma. According...
BI-765179 by Boehringer Ingelheim International for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...
BI-765179 by Boehringer Ingelheim International for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC)....
BI-765179 by Boehringer Ingelheim International for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Head And Neck Squamous Cell...
BI-765179 by Boehringer Ingelheim International for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
BI-765179 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC)....